Home › Therapeutic areas › GI/Hepatology › Inflammatory Bowel Disease
Inflammatory Bowel Disease (4 companies)
Companies with an active program in Inflammatory Bowel Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ABSI | Absci | DermatologyGI/Hepatology+1 | 1 | Phase 1 | $1.75B | 6 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 1 | Phase 2 | $69.0M | 9 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 1 | Phase 3 | $3.59B | 9 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 1 | Approved | $1.85B | 5 |
No companies match.